Adaptive Biotechnologies Corp
Adaptive Biotechnologies' COO Julie Rubinstein sold $1.01m in stock and exercised options for $432,706 in October 2026. ADPT stock is near its 52-week high at $29.84, up 106% year-over-year. Q2 results showed a wider-than-expected loss but revenue beat estimates. Analysts raised price targets, with BTIG and Goldman Sachs at $34 and $35 respectively, while Guggenheim set a $25 target.
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.46 ($27.57–$29.67, $1.01M total) across 5 trades over 2026-10-01 to 2026-10-05 under a Rule 10b5-1 trading plan.
LO FRANCIS (Chief People Officer) sold 26,792 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.28 ($27.52–$28.61, $0.76M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ADPT (Adaptive Biotechnologies Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ADPT coverage spans financial news, insider activity and market movers.
In the last 30 days, ADPT insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($5.0M). The most active reporter was RUBINSTEIN JULIE, President and COO, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may create slight downward pressure on ADPT.
The insider sale may create modest selling pressure on ADPT.
The insider sale may create modest selling pressure on ADPT.
Analyst upgrade likely supports upside pressure on ADPT.
Analyst initiation and buy rating suggest potential price appreciation.
AlphAI scores every news story that mentions ADPT with an AI model for sentiment and relevance, and aggregates insider trades from Adaptive Biotechnologies Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Adaptive Biotechnologies' COO Julie Rubinstein sold $1.01m in stock and exercised options for $432,706 in October 2026. ADPT stock is near its 52-week high at $29.84, up 106% year-over-year. Q2 results showed a wider-than-expected loss but revenue beat estimates. Analysts raised price targets, with BTIG and Goldman Sachs at $34 and $35 respectively, while Guggenheim set a $25 target.
2 min readRUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.46 ($27.57–$29.67, $1.01M total) across 5 trades over 2026-10-01 to 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readLO FRANCIS (Chief People Officer) sold 26,792 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.28 ($27.52–$28.61, $0.76M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readGoldman Sachs initiated coverage on Adaptive Biotechnologies (ADPT) with a Buy rating and a $35 price target, citing growth potential. The company's market cap is $4.55B. GuruFocus values ADPT at $11.61, suggesting it's 145.6% overvalued, with a GF Score of 72/100. Insider activity shows mixed sentiment.
2 min readGoldman Sachs initiated coverage on Adeptus Biotechnologies (NASDAQ:ADPT) with a buy rating and $35 price target, citing leadership in minimal residual disease testing. The stock trades at $28.51, up 112% over the past year. The company reported $308M revenue with 50% growth but a net loss of $64M. Goldman Sachs expects growth from electronic medical record integration and blood-based testing. InvestingPro analysis suggests the stock is overvalued.
2 min readSeveral biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.
2 min readAdaptive Biotechnologies (ADPT) reported updated NCCN guidelines for multiple myeloma, which include its clonoSEQ test and expand testing time points. The company saw 43% year-over-year growth in clonoSEQ tests and raised full-year MRD revenue guidance to $268M-$278M. While the guidelines may boost testing frequency, competition and reimbursement remain factors.
2 min readBTIG kept a Buy rating on Adaptive Biotechnologies with a $34 price target, suggesting a 22% upside from the Sep 21 close. The firm cited strong revenue growth, including a 22% YoY increase to $72M in Q2'26, and NCCN guideline updates supporting clonoSEQ for multiple myeloma assessments.
1 min readBTIG raised its price target for Adeptus Biotechnologies (ADPT) to $34 from $25, citing updated cancer guidelines that feature its clonoSEQ assay. The stock has gained 109% over the past year. Adaptive Biotechnologies reported Q2 revenue of $71.6M, up 22% YoY, but missed earnings estimates. Guggenheim and BTIG also raised their price targets for Adaptive Biotechnologies.
2 min readLO FRANCIS (Chief People Officer) sold 115,406 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.06 ($28.02–$28.57, $3.24M total) across 2 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min read
